By evaluating the copy number aberration (CNA) in bone marrow cells and/or circulating cell free DNA (cfDNA) via shallow whole genome sequencing (sWGS), in conjunction with conventional cytogenetics, LeukoPrint^® makes leukemia diagnosis, molecular subtyping, prognostic stratification and treatment responds monitoring more precise and comprehensive.